Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study
Crossref DOI link: https://doi.org/10.1007/s12325-016-0287-8
Published Online: 2016-02-03
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sheldon, Eric
Schwickart, Martin
Li, Jing
Kim, Keunpyo
Crouch, Sarah
Parveen, Shaista
Kell, Chris
Birrell, Claire
Funding for this research was provided by:
MedImmune
Text and Data Mining valid from 2016-02-01